Evidence map›Paper›PMID 22402816›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2012

A Pneumocystis jirovecii pneumonia outbreak in a single kidney-transplant center: role of cytomegalovirus co-infection.

R U Pliquett, A Asbe-Vollkopf, P M Hauser, L L Presti, K P Hunfeld, A Berger, E H Scheuermann, O Jung, H Geiger, I A Hauser

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. Outcomes of concomitantAnnals of medicine · 2026
    Article
  2. JHLT open · 2025
    Article
  3. Article
  4. Trends in the Epidemiology ofJournal of fungi (Basel, Switzerland) · 2023
    Review
  5. The Pathogenesis and Diagnosis ofJournal of fungi (Basel, Switzerland) · 2022
    Review
  6. Article
  7. Consensus Multilocus Sequence Typing Scheme forJournal of fungi (Basel, Switzerland) · 2020
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Journal of fungi (Basel, Switzerland) · 2015
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Reply to Hauser et Al.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

R U PliquettDepartment of Nephrology, Johann Wolfgang Goethe University, Frankfurt/M., Germany. rainer.pliquett@medizin.uni-halle.de
A Asbe-Vollkopf
P M Hauser
L L Presti
K P Hunfeld
A Berger
E H Scheuermann
O Jung
H Geiger
I A Hauser
Goethe University Frankfurt · DEUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pneumocystis jirovecii pneumonia (PCP) and cytomegalovirus (CMV) infection represent possible complications of medical immunosuppression. Between 2005 and 2010, non-human immunodeficiency virus (HIV) PCP patients admitted to a nephrology unit were analyzed for outcome, CMV comorbidity, and patient-to-patient contacts prior to PCP. In contrast to 2002-2004 (no cases) and 2008-2010 (10 cases), a PCP outbreak of 29 kidney-transplant recipients and one patient with anti-glomerular basement membrane disease occurred between 2005 and 2007. None of the patients were on PCP chemoprophylaxis. In four PCP patients, the genotyping data of bronchoalveolar lavage specimen showed an identical Pneumocystis strain. PCP cases had a higher incidence of CMV infection (12 of 30 PCP patients) and CMV disease (four patients) when compared to matched PCP-free controls (p < 0.05). Cotrimoxazole and, if applicable, ganciclovir were started 2.0 ± 4.0 days following admission, and immunosuppressive medication was reduced. In-hospital mortality was 10% and the three-year mortality was 20%. CMV co-infection did not affect mortality. CMV co-infection more frequently occurred during a cluster outbreak of non-HIV PCP in comparison to PCP-free controls. Here, CMV awareness and specific therapy of both CMV infection and PCP led to a comparatively favorable patient outcome. The role of patient isolation should be further investigated in incident non-HIV PCP.

Indexed as

Disease OutbreaksAdultAgedAntifungal AgentsAntiviral AgentsCase-Control StudiesCoinfectionCross InfectionCytomegalovirusCytomegalovirus InfectionsFemaleGanciclovirGenotypeHumansImmunocompromised HostKidney TransplantationAntifungal AgentsAntiviral AgentsGanciclovirTrimethoprim, Sulfamethoxazole Drug Combination

Identifiers

PMID22402816
OpenAlexW2145021535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.